NCT05183178CompletedPhase 4
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome-a Stepped Wedge Cluster Randomized Evaluation in the SWEDEHEART-registry
Source: ClinicalTrials.gov · Last updated 8 Jul 2026
Brief summary (registry, in English)
This study proposes to conduct the switch from ticagrelor to prasugrel in an organized stepwise manner, to allow for the evaluation of the relative efficacy of prasugrel versus ticagrelor using a stepped-wedge cluster randomized trial design.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 17095 (actual)
- First submitted
- 19 Nov 2021
- Start date
- 1 Feb 2022
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- Vastra Gotaland Region
- Diseases
- Coronary artery disease
- NCT number
- NCT05183178
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 17095
- From 1 Feb 2022 to the primary completion date, 31 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patients hospitalized for Acute coronary syndrome, as defined by the European Society of Cardiology, at any hospital participating in the study, and included in the SWEDEHEART registry during index hospitalization
- Age ≥ 18 years.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dep. Cardiology, Skånes universitetssjukhus Coordinator of this site? Confirm its status | Lund | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.